PROKIDNEY CORP.
PROKNasdaq
$1.62
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↓ -56.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$889,000.00
Net Income (TTM)
-$72.3M
Free Cash Flow (TTM)
-$150.1M
Gross Margin
—
Operating Margin
-18959.7%
Net Margin
-8131.5%
ROE
7.1%
ROIC
—
Debt / Equity
—
Net Cash
$101.9M
Return 1Y
-54.0%
Company profile
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
- CEO
- Timothy A. Bertram
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3
- Headquarters
- North Carolina
- Website
- prokidney.com
Management & directors
- Girolamo Todd CChief Legal Officer
- Weber Darin J.Chief Regulatory Officer
Roles derived from SEC Form 4 filings.
Earnings
PROK Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$226,000.00↓ -1.7%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $76,000.00 | $893,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$27.0M | -$55.1M | -$153.0M | -$151.5M | -$183.7M | -$165.0M |
| Net income | — | -$55.1M | — | -$35.5M | -$61.2M | -$69.0M |
| Diluted EPS | — | — | -$0.23 | — | — | — |
| Operating cash flow | -$25.2M | -$50.3M | -$77.1M | -$90.1M | -$126.4M | -$120.1M |
| Free cash flow | -$30.6M | -$55.5M | -$78.9M | -$124.3M | -$155.9M | -$135.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -241678.9% | -18477.8% |
| Net margin | — | — | — | — | -80507.9% | -7725.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $76,000.00 | $230,000.00 | $221,000.00 | $217,000.00 | $225,000.00 | $226,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$43.1M | -$49.0M | -$51.6M | -$41.4M | -$39.7M | -$38.5M | -$45.4M | -$44.9M |
| Net income | -$12.5M | -$17.9M | -$21.3M | -$16.7M | -$16.6M | -$16.5M | -$19.2M | -$20.0M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$38.3M | -$29.2M | -$24.2M | -$29.6M | -$31.4M | -$26.6M | -$32.5M | -$41.7M |
| Free cash flow | -$38.9M | -$31.6M | -$49.7M | -$30.7M | -$34.5M | -$31.8M | -$38.3M | -$45.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | -67856.6% | -17994.8% | -17967.9% | -17759.9% | -20164.9% | -19881.9% |
| Net margin | — | — | -27997.4% | -7275.7% | -7489.6% | -7589.4% | -8547.1% | -8865.9% |
Company news
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-12 | Girolamo Todd C· Chief Legal Officer | C | 163,857 | $0.00 | $0.00 | filing |
| 2026-04-28 | INMOBILIARIA CARSO S A DE C V | C | 63,118,645 | $0.00 | $0.00 | filing |
| 2025-11-13 | Pereira Brian JG | Sale | 447,803 | $2.37 | $1.1M | filing |
| 2025-11-13 | Pereira Brian JG | Sale | 54,333 | $2.37 | $128,769.21 | filing |
| 2025-11-12 | Pereira Brian JG | Sale | 227,431 | $2.72 | $619,362.84 | filing |
| 2025-11-12 | Pereira Brian JG | Sale | 27,595 | $2.72 | $75,152.22 | filing |
| 2025-07-08 | Weber Darin J.· Chief Regulatory Officer | Sale | 103,480 | $3.02 | $312,509.60 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.